Dose calculations for [(131)i] meta-iodobenzylguanidine-induced bystander effects
Gow, M D and Seymour, C B and Mairs, R J and Boyd, Marie and Prestiwch, W V and Mothersill, C E (2014) Dose calculations for [(131)i] meta-iodobenzylguanidine-induced bystander effects. Dose-response : a publication of International Hormesis Society, 12 (1). pp. 1-23. (https://doi.org/10.2203/dose-response.13-001.Mothe...)
Full text not available in this repository.Request a copyAbstract
Targeted radiotherapy is a potentially useful treatment for some cancers and may be potentiated by bystander effects. However, without estimation of absorbed dose, it is difficult to compare the effects with conventional external radiation treatment. Using the Vynckier - Wambersie dose point kernel, a model for dose rate evaluation was created allowing for calculation of absorbed dose values to two cell lines transfected with the noradrenaline transporter (NAT) gene and treated with [(131)I]MIBG. The mean doses required to decrease surviving fractions of UVW/NAT and EJ138/NAT cells, which received medium from [(131)I]MIBG-treated cells, to 25 - 30% were 1.6 and 1.7 Gy respectively. The maximum mean dose rates achieved during [(131)I]MIBG treatment were 0.09 - 0.75 Gy/h for UVW/NAT and 0.07 - 0.78 Gy/h for EJ138/NAT. These were significantly lower than the external beam gamma radiation dose rate of 15 Gy/h. In the case of control lines which were incapable of [(131)I]MIBG uptake the mean absorbed doses following radiopharmaceutical were 0.03 - 0.23 Gy for UVW and 0.03 - 0.32 Gy for EJ138. [(131)I]MIBG treatment for ICCM production elicited a bystander dose-response profile similar to that generated by external beam gamma irradiation but with significantly greater cell death.
ORCID iDs
Gow, M D, Seymour, C B, Mairs, R J, Boyd, Marie ORCID: https://orcid.org/0000-0003-4120-2218, Prestiwch, W V and Mothersill, C E;-
-
Item type: Article ID code: 50639 Dates: DateEventJanuary 2014PublishedSubjects: Medicine > Pharmacy and materia medica Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Technology and Innovation Centre > Advanced Science and Technology
Technology and Innovation Centre > BionanotechnologyDepositing user: Pure Administrator Date deposited: 02 Dec 2014 10:54 Last modified: 11 Nov 2024 10:52 URI: https://strathprints.strath.ac.uk/id/eprint/50639